NDA 221251, held by Regeneron Pharmaceuticals. Cemdisiran.
As of Nov 22, 2026, NDA 221251 (Livsayis), held by Regeneron Pharmaceuticals, was first approved by FDA on Nov 18, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2026 | Original applicationNew molecular entity · Priority review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Livsayis189MG/ML · vial;single-dose | Cemdisiran | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters